113. Muscular dystrophy Clinical trials / Disease details

Clinical trials : 622 / Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04226924 (ClinicalTrials.gov)	June 15, 2017	15/7/2019	Treatment of Oculopharyngeal Muscular Dystrophy With Trehalose	A Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Trial of Trehalose for the Treatment of	Oculopharyngeal Muscular Dystrophy	Drug: Trehalose	Bioblast Pharma Ltd.	NULL	Withdrawn	50 Years	70 Years	All	0	Phase 2	Canada
2	NCT02328482 (ClinicalTrials.gov)	January 2015	25/12/2014	Continuation Protocol to Protocol BBCO-001	A Pivotal, Multicenter, Open-label, Randomized Withdrawal, Non-Treatment Concurrent Control Study to Assess the Safety, Tolerability, and Efficacy of Cabaletta® in OPMD Patients Who Participated in Study BBCO-001	Muscular Dystrophy, Oculopharyngeal (OPMD)	Drug: Tehalose 30gr	Bioblast Pharma Ltd.	NULL	Completed	18 Years	80 Years	All	9	Phase 3	Canada
3	NCT02015481 (ClinicalTrials.gov)	February 2014	8/12/2013	Safety Tolerability and Efficacy Study of Cabaletta to Treat Oculopharyngeal Muscular Dystrophy (OPMD) Patients	Multi-Center, Dose-Escalation Study, to Assess Safety, Tolerability and Efficacy of Intravenous Cabaletta® in OPMD Patients	Oculopharyngeal Muscular Dystrophy	Drug: Cabaletta	Bioblast Pharma Ltd.	NULL	Completed	18 Years	80 Years	All	25	Phase 2	United States;Canada;Israel